Study on Ayurvedic medicines to reduce chemotherapy side effects and improve quality of life in cancer patients

An Open Label Randomized Controlled Clinical Study to Evaluate the Efficacy of Kamadugha Rasa Muktayukta Kharjuradi Mantha and Dadimadi Ghritha as an Adjuvant in Managing the Side Effects and Improving the Quality of Life of Subjects Undergoing Chemotherapy in Cancer - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/07/113888

Enrollment

Registered

2026-07-13

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged 18 to 80 years. Diagnosed cases of cancer irrespective of type or site. Undergoing chemotherapy. Patients who have completed at least one cycle of chemotherapy. Willing to participate and provide written informed consent.

Exclusion criteria

Exclusion criteria: Patients unable to take oral medications. Terminally ill patients. Patients with uncontrolled diabetes mellitus. Patients with uncontrolled hypertension. Patients with severe systemic disorders likely to interfere with the study.

Design outcomes

Primary

Measure	Time frame
Improvement in quality of life and reduction in chemotherapy induced adverse effects among cancer patients receiving Kamadugha Rasa Mukta Yukta, Kharjuradi Mantha and Dadimadi Ghrita as an adjuvant to standard chemotherapy, assessed using WHOQOL BREF, Karnofsky Performance Scale and MD Anderson Symptom Inventory.Timepoint: week 0 baseline week 2 week 4 week 6 week 8 week 10 week 12 end of intervention week 14 post follow up	—

Measure

Time frame

Improvement in quality of life and reduction in chemotherapy induced adverse effects among cancer patients receiving Kamadugha Rasa Mukta Yukta, Kharjuradi Mantha and Dadimadi Ghrita as an adjuvant to standard chemotherapy, assessed using WHOQOL BREF, Karnofsky Performance Scale and MD Anderson Symptom Inventory.Timepoint: week 0 baseline week 2 week 4 week 6 week 8 week 10 week 12 end of intervention week 14 post follow up

—

Secondary

Measure	Time frame
Improvement in WHOQOL BREF score.Timepoint: Baseline, 12 weeks, 14 weeks.;Improvement in Karnofsky Performance Scale score.Timepoint: Baseline, 12 weeks, 14 weeks.;Reduction in symptom burden assessed using MD Anderson Symptom InventoryTimepoint: Baseline, after each chemotherapy cycle, 12 weeks, 14 weeks.;Improvement in body weightTimepoint: Baseline and at of 12 weeks	—

Countries

India

Contacts

Public ContactDr Ananta S Desai

Government Ayurveda Medical College and Hospital Mysuru

anantdesai30@gmail.com9448185896

Outcome results